Zynex Appoints Rachelle Van Burkleo Vice President of Sales

ENGLEWOOD, Colo., March 30, 2020 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that it has hired Rachelle (Chelle) Van Burkleo as its Vice President of Sales.

Chelle brings more than 20 years of experience and an exceptional level of expertise in med-tech device sales. Previously, Chelle was Vice President of Sales and Marketing at WiscMed where she led strategic marketing initiatives and business sales plan development.

Prior to WiscMed, Chelle was a senior sales and business development leader with Welch Allyn (Hillrom), a global medical device manufacturer. She started her career at Welch Allyn in 1995, working with physicians to advance frontline care. Throughout her career, she has taken on numerous roles of progressive responsibility ultimately helping healthcare systems improve outcomes, lower cost of care and improve both the clinician and patient experience.

Chelle holds a Texas Executive Education certificate in general management and a bachelor's degree in business from the Red McCombs School of Business at the University of Texas – Austin. 

Thomas Sandgaard, CEO, said: "We are excited to have Chelle on board to lead our growing sales organization covering the market for prescription-strength electrotherapy for pain management. We continue to grow our sales force across the country and expect to have 400 sales reps covering the US before the end of the year."

About Zynex, Inc. 
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex also has a blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: www.zynex.com.

Safe Harbor Statement
This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact.

In some cases, you can identify forward-looking statements by terminology, such as "expects," "anticipates," "intends," "estimates," "plans," "believes," "seeks," "may," "should," "could," "will," "future," "projects," "strategy," or the negative of such terms or other similar expressions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2019.

Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact: Zynex, Inc. (303) 703-4906 
Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel